{"name":"Janssen Pharmaceutica","slug":"janssen-pharmaceutica","ticker":"","exchange":"","domain":"janssenpharmaceutica.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"cardiovascular","drugs":[{"name":"Erdafitinib Intravesical Delivery System","genericName":"Erdafitinib Intravesical Delivery System","slug":"erdafitinib-intravesical-delivery-system","indication":"Other","status":"phase_1"},{"name":"ITCZ-IV","genericName":"ITCZ-IV","slug":"itcz-iv","indication":"Invasive aspergillosis","status":"phase_3"},{"name":"JNJ-54861911, 50 mg","genericName":"JNJ-54861911, 50 mg","slug":"jnj-54861911-50-mg","indication":"Other","status":"phase_2"},{"name":"JNJ-56021927 240 Milligram","genericName":"JNJ-56021927 240 Milligram","slug":"jnj-56021927-240-milligram","indication":"Other","status":"phase_1"},{"name":"JNJ-64042056","genericName":"JNJ-64042056","slug":"jnj-64042056","indication":"Other","status":"phase_2"},{"name":"JNS001","genericName":"JNS001","slug":"jns001","indication":"Other","status":"phase_3"},{"name":"Miconazole plus Hydrocortisone","genericName":"Miconazole plus Hydrocortisone","slug":"miconazole-plus-hydrocortisone","indication":"Other","status":"marketed"},{"name":"Placebo A (After CP)","genericName":"Placebo A (After CP)","slug":"placebo-a-after-cp","indication":"Other","status":"phase_3"},{"name":"Placebo B (After CP)","genericName":"Placebo B (After CP)","slug":"placebo-b-after-cp","indication":"Other","status":"phase_3"},{"name":"early initiation of treatment with Risperdal Consta","genericName":"early initiation of treatment with Risperdal Consta","slug":"early-initiation-of-treatment-with-risperdal-consta","indication":"Other","status":"marketed"},{"name":"routine initiation of treatment with Risperdal Consta","genericName":"routine initiation of treatment with Risperdal Consta","slug":"routine-initiation-of-treatment-with-risperdal-consta","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"CNTO 148","genericName":"CNTO 148","slug":"cnto-148","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CNTO 1959","genericName":"CNTO 1959","slug":"cnto-1959","indication":"Psoriasis","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"JNS020QD","genericName":"JNS020QD","slug":"jns020qd","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"ITCZ Oral Solution","genericName":"ITCZ Oral Solution","slug":"itcz-oral-solution","indication":"Oropharyngeal candidiasis","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Risperidone Long acting injectable","genericName":"Risperidone Long acting injectable","slug":"risperidone-long-acting-injectable","indication":"Schizophrenia","status":"marketed"}]}],"pipeline":[{"name":"JNS020QD","genericName":"JNS020QD","slug":"jns020qd","phase":"phase_3","mechanism":"JNS020QD is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CNTO 148","genericName":"CNTO 148","slug":"cnto-148","phase":"phase_3","mechanism":"CNTO 148 is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling in immune-mediated diseases.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"CNTO 1959","genericName":"CNTO 1959","slug":"cnto-1959","phase":"phase_2","mechanism":"CNTO 1959 is a monoclonal antibody that inhibits IL-23 signaling to reduce inflammatory immune responses.","indications":["Psoriasis","Inflammatory bowel disease"],"catalyst":""},{"name":"Erdafitinib Intravesical Delivery System","genericName":"Erdafitinib Intravesical Delivery System","slug":"erdafitinib-intravesical-delivery-system","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ITCZ Oral Solution","genericName":"ITCZ Oral Solution","slug":"itcz-oral-solution","phase":"phase_3","mechanism":"ITCZ (itraconazole) is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Oropharyngeal candidiasis","Esophageal candidiasis","Systemic fungal infections (aspergillosis, blastomycosis, histoplasmosis, cryptococcosis)"],"catalyst":""},{"name":"ITCZ-IV","genericName":"ITCZ-IV","slug":"itcz-iv","phase":"phase_3","mechanism":"ITCZ-IV is an intravenous formulation of itraconazole, a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Invasive aspergillosis","Blastomycosis","Histoplasmosis","Cryptococcosis"],"catalyst":""},{"name":"JNJ-54861911, 50 mg","genericName":"JNJ-54861911, 50 mg","slug":"jnj-54861911-50-mg","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-56021927 240 Milligram","genericName":"JNJ-56021927 240 Milligram","slug":"jnj-56021927-240-milligram","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-64042056","genericName":"JNJ-64042056","slug":"jnj-64042056","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNS001","genericName":"JNS001","slug":"jns001","phase":"phase_3","mechanism":"JNS001 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to modulate immune response.","indications":[],"catalyst":""},{"name":"Miconazole plus Hydrocortisone","genericName":"Miconazole plus Hydrocortisone","slug":"miconazole-plus-hydrocortisone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo A (After CP)","genericName":"Placebo A (After CP)","slug":"placebo-a-after-cp","phase":"phase_3","mechanism":"Placebo A is an inert control substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo B (After CP)","genericName":"Placebo B (After CP)","slug":"placebo-b-after-cp","phase":"phase_3","mechanism":"Placebo B is an inert control substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Risperidone Long acting injectable","genericName":"Risperidone Long acting injectable","slug":"risperidone-long-acting-injectable","phase":"marketed","mechanism":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (maintenance treatment)","Irritability associated with autism spectrum disorder","Aggression and behavioral disturbances in patients with psychotic disorders"],"catalyst":""},{"name":"early initiation of treatment with Risperdal Consta","genericName":"early initiation of treatment with Risperdal Consta","slug":"early-initiation-of-treatment-with-risperdal-consta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"routine initiation of treatment with Risperdal Consta","genericName":"routine initiation of treatment with Risperdal Consta","slug":"routine-initiation-of-treatment-with-risperdal-consta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPbFJacHktaHNQanN6TFI0ODh0VnNnRnZMbzhBNmtDN1JTTERwRjN3VmJScWYzTXZLY1E0RVBJV1kxNXZmVEg5cGloblVlM2ZVdTBLVFdfYXk0TjBGWTEtTF8ycHpWQlZMVzlRMWNFUU9tMndLcW5SYlI1RUdIQzI1cFBxZFRBbE9BcXZMd0RJNnFid0UyelZ6YlhaQQ?oc=5","date":"2026-03-30","type":"regulatory","source":"The Japan Times","summary":"ADHD medication in short supply in Japan as demand soars - The Japan Times","headline":"ADHD medication in short supply in Japan as demand soars","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQbHFuMTFKc0Zpd29fXzZiQ0JVc2ViRGYxM2V4RnU3VmdrTlFkdEdNdlZzX2pJX2RkZ2h2ZkxCOF91NEgwd21zWVlTNUpPX3ZGSnlQdnVIbUl2X3dIcWdOTE1NczYzTjItSUVhTmExcVRjWHg0WE9jenN4ZVJRQmZhYW1QeUlzQVRkeFhWY2tDcjZ5VlNOSGxuUkFNS1dsY0RJdXpFZEEzal8zNmdjT0pMV0Q4Wi16czJLM1BjcUtJYzZFTXZzVUhJTVpqTjBpVVhXRndGamE2NA?oc=5","date":"2025-12-17","type":"patent","source":"Pearce IP","summary":"Federal Court of Australia Awards Janssen First Pharmaceutical Patent Preliminary Injunction in 7 Years - Pearce IP","headline":"Federal Court of Australia Awards Janssen First Pharmaceutical Patent Preliminary Injunction in 7 Years","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-01","type":"patent","source":"The Hindu","summary":"Lupin launches generic of Janssen Pharma’s VTE drug in U.S. - The Hindu","headline":"Lupin launches generic of Janssen Pharma’s VTE drug in U.S.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOWVY3NDRnLV9CSFhhZ1RkNHJlZjRrX3NHTmVaa3FycmxEOHJMU05XZGhQV3VkWlE1cFYyaWVIQlBvTnNwZFpBdS1WRWlreXpWZndwWTN0aTBkWHVDS0FYWFBzU0JtQ0FTYjZXaVhfZEtxV0YyOGdYNkstMG4yNkk5MnE5Uk5UR05fUzIzc1M3ZTZxM1dMNVRqS1p2b1NPTVB3U2Y4THNR?oc=5","date":"2025-06-10","type":"patent","source":"JUVE Patent","summary":"Court of Appeal implements CJEU ruling in Janssen’s dispute with INPI - JUVE Patent","headline":"Court of Appeal implements CJEU ruling in Janssen’s dispute with INPI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5HYUdFUFBuWTEtVjExVHdpbGliQ1lqajdhUjByT3lneGpaQWZsRnppNnZRaWhMZXJyaU1Zbmx5dThSOHZkQ2s4VnlRWWRlUnBFcmFzMzAyZUdBX2lFem8ybERMdk9nTEpHOE9xcXVB0gFyQVVfeXFMTURtcW91cnhQUmdZb1o5amVQbjhvS29qRlU1MG9xdkNhSFVpUmY3SHktUWQ1NExYcGRrZXFhUHpLdl8yS19KS0cxTFNaQzZUc2ZHaU1uNk5ETVFvdEdoSUc2WXdrRmJlcGNDaEpCTnh3Qnln?oc=5","date":"2025-05-27","type":"pipeline","source":"koreabiomed.com","summary":"Samjin Pharmaceutical appoints former Janssen GM as president - koreabiomed.com","headline":"Samjin Pharmaceutical appoints former Janssen GM as president","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNQ2lsbVgwbGdiZDBfTlRzMXhnVTNLWlJrR2ZRcGRwQ3JveDluVEF6X08wc3JRd1lobzhFR3kyREFoa1pKNGFFY3dxeFJfa1ZpZzd0MUd3cGZvQVpVY2dqMFVCVWhkcTRmR0tVaWRWNWpfbzVkVzRZdUFCd0UyWG83TjVWYTBvRFFlVFJMeUplMEtxZ3NEdFlkdXlYaHRNTlAxR3plMFdDVXh2THU4dE5NdGRZTm85SHhRak83MzhTWHJ1NWM5OUR2aXNfSFpWS1R5R3Q1QUJ1alQyeE5pa3RjRnI5SjgyVjFQWENvSjhOLWIxZ3FCbm9SWg?oc=5","date":"2024-04-19","type":"deal","source":"Pharmaceutical Executive","summary":"Essential Pharma Acquires Reminyl, a Cholinesterase Inhibitor to Treat Mild to Moderately Severe Dementia from Janssen Pharmaceutica NV - Pharmaceutical Executive","headline":"Essential Pharma Acquires Reminyl, a Cholinesterase Inhibitor to Treat Mild to Moderately Severe Dementia from Janssen P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5FVVUza1JtTEVxUWtEaGxHRkg0Ym82Um5QbE5GLXVjZGMtZkZ2QzN2ZUlYaGc4XzM4YTFCeHZLb1dLNGdTVU1ZZFhOTUxKVjVzZnZnczEtekRMSVBRNmtXQW5qejlsdUFYWkZLTnJVRHplbDlLMkwtVy1zNEg?oc=5","date":"2024-04-18","type":"deal","source":"Pharmaceutical Technology","summary":"Essential Pharma acquires Reminyl from Janssen Pharmaceutica - Pharmaceutical Technology","headline":"Essential Pharma acquires Reminyl from Janssen Pharmaceutica","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOOTcxRUt6T19GbHNEVXE4c0NkRFhaZHZWNFRKbXFNZUxPWlNZT1NKbHNLdnBHYmplLXkxcTItSTBXWEFfWTdZQkxmQXdESnJGSm93RHVyQXg2Sko1aHJuWWpseEhhU2dNNktrVExSWVJUN2FMMEJlMXVuaUlTWkl6WlBfc0h6WUVZOFlMNWsxdTNfc1lUYl9kSkY2OURtMnpj?oc=5","date":"2023-09-15","type":"trial","source":"BioPharma Dive","summary":"J&J to phase out Janssen name in corporate rebrand - BioPharma Dive","headline":"J&J to phase out Janssen name in corporate rebrand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPMVJtRGt2UkgyMWFxTmdsY0REakR2VXhJRkZGa2tRWmxXczhIVDN5elJBNHVxUlp2ZllaZkxQLUtibkdwTXZOemFWSVVJczNxcVNZX3BxeHdNMHRocWZTZWU1N0xMNHIxLWU0eFR6LUwyenY3bDRiY2dfY1F2dktXbDJsSzBSNm1vdEdNNEs1QnAzMTA?oc=5","date":"2023-09-15","type":"pipeline","source":"European Pharmaceutical Review","summary":"Janssen rebrands its identity - European Pharmaceutical Review","headline":"Janssen rebrands its identity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQRmtRT251c041dThFQldiREtXTW9LeVNDcUNxaWpLaGViQXczczdRRXA0VTVRcGt4YnFJTk9WaE1KR3cyUjZBblJnREJHdFgyVV83TlBicEhSUUhkMlE3N1dKMXpISzRZR285MWxmQmE5Z2dtVDVDZXJZNF9oM3phbnBaT0NubGtsVTI3Rmw3YjdPWHFGTFBXbDVHaWx0cWZLOXdtRnptVXUyeWhpVGZuNVFEUkdQd3pFQWJBemJvZw?oc=5","date":"2023-09-14","type":"pipeline","source":"Fierce Pharma","summary":"After Kenvue spinoff, J&J says it's 'uniting' Janssen and medtech segments under one brand - Fierce Pharma","headline":"After Kenvue spinoff, J&J says it's 'uniting' Janssen and medtech segments under one brand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNUW5QVWF6S2s0UWk2bFRkOGhvSUhQenpiaGpnNHYzd1diTEdQMnlYMkpFbHVlVXNHQzlBT25aWTVLWWtWaXYyc0YzQWh3RGtRWUQ4QUc2dTNYVG9sdkhTTUlmUzBuR2dDZlFLc1Bya1dsYTAyNHkyaFFtUzVRRVoyUkRIaGFVYno4ZmhWcVlSSWR3X2pVYmtKY183Nk0xclk?oc=5","date":"2022-05-18","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Janssen (Johnson & Johnson’s pharmaceutical segment) - drugdiscoverytrends.com","headline":"Janssen (Johnson & Johnson’s pharmaceutical segment)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQc3l6Q1UxQ1VsdG0wd1RacktoVThZdzN3bW9XSVZuRThSa2thT0FibHVtNlF0TExCVTUzQ21MMGdxdXNGei1nRjhlN2VWeHpIbXd4RzQxLXFXUVRQZDZzVVMxYnVjc2pXc1FWRDF1MGh4cnRiRmFSZTY5Q1ZBQW1pYnBqVGlyUlE5MnVCNUk5eGJlMTF4NkhUREhMSGJiMlNKTFJ5clBNQzdzempPN1BV?oc=5","date":"2015-09-11","type":"pipeline","source":"Johnson & Johnson","summary":"The legacy of Dr. Paul Janssen: How a “funny idea” helped change the course of modern medicine - Johnson & Johnson","headline":"The legacy of Dr. Paul Janssen: How a “funny idea” helped change the course of modern medicine - Johnson & Johnson","sentiment":"neutral"}],"patents":[],"drugCount":16,"phaseCounts":{"phase_3":7,"phase_2":3,"phase_1":2,"marketed":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}